Table 1 Characteristics of schizophrenia trials conducted in Africa
From: Schizophrenia trials conducted in African countries: a drop of evidence in the ocean of morbidity?
|  | STUDIES (n = 38) No % |
|---|---|
Type of comparison | |
Typical AP versus typical AP | 12 (31.58) |
Typical AP versus placebo | 3 (7.89) |
Typical AP versus no treatment | 1 (2.63) |
Typical AP versus atypical AP | 6 (15.79) |
Atypical AP versus atypical AP | 4 (10.53) |
Other pharmacological interventions | 7 (18.42) |
Non pharmacological interventions | 5 (13.16) |
Year of publication | |
1970–1985 | 9 (23.68) |
1986–2000 | 9 (23.68) |
2001–2010 | 20 (52.64) |
Sample size | |
Min-20 | 4 (10.81) |
21–40 | 12 (32.43) |
41–60 | 10 (27.03) |
61-Max | 11 (29.73) |
Arms | |
Two arms | 34 (89.47) |
Three arms or more | 4 (10.53) |
Weeks of follow-up | |
< 6 weeks | 16 (42.43) |
6–12 weeks | 9 (24.24) |
13–24 weeks | 7 (18.18) |
> 24 weeks | 6 (15.15) |
Blinding | |
Open label | 6 (15.79) |
Single blind | 7 (18.42) |
Double blind | 18 (47.37) |
Unclear | 7 (18.42) |
Diagnostic criteria | |
Unclear | 9 (23.68) |
DSM† − ICD††| 25 (65.79) |
Clinical diagnosis | 4 (10.53) |
Number of outcomes | |
Min-5 | 13 (34.21) |
6–10 | 14 (36.84) |
11-Max | 11 (28.95) |
Ethics committee approval | |
Unclear | 16 (42.11) |
Yes | 22 (57.89) |
Sponsor (drug company) | |
Unclear | 20 (52.63) |
Yes | 15 (39.48) |
Independent study | 3 (7.89) |